M
Marie Scully
Researcher at University College London
Publications - 178
Citations - 7826
Marie Scully is an academic researcher from University College London. The author has contributed to research in topics: Thrombotic thrombocytopenic purpura & Medicine. The author has an hindex of 37, co-authored 142 publications receiving 5568 citations. Previous affiliations of Marie Scully include Royal Free London NHS Foundation Trust & University College London Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.
Marie Scully,Beverley J. Hunt,Sylvia Benjamin,Ri Liesner,Peter Rose,Flora Peyvandi,Betty Y.Y. Cheung,Samuel J. Machin +7 more
TL;DR: The objective of this guideline is to provide healthcare professionals with clear, up-to-date, and practical guidance on the management of TTP and relatedThrombotic microangiopathies, defined by thrombocytopenia, microangypathic haemolytic anaemia (MAHA) and small vessel thromBosis.
Journal ArticleDOI
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
Marie Scully,Deepak Singh,Robert Lown,Anthony Poles,Tom Solomon,Marcel Levi,David Goldblatt,Pavel Kotoucek,William John Thomas,William Lester +9 more
TL;DR: The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome (SARS-CoV-2) as mentioned in this paper.
Journal ArticleDOI
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Marie Scully,Spero R. Cataland,Flora Peyvandi,Paul Coppo,Paul Knöbl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,Filip Callewaert,Debjit Biswas,Hilde De Winter,R.K. Zeldin,Hercules Investigators +13 more
TL;DR: In this paper, a double-blind, controlled trial was conducted to evaluate the effect of caplacizumab on platelet normalization and recurrence of TTP.
Journal ArticleDOI
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi,Marie Scully,Johanna A. Kremer Hovinga,Spero R. Cataland,Paul Knöbl,Haifeng Wu,Andrea Artoni,John-Paul Westwood,Magnus Mansouri Taleghani,Bernd Jilma,Filip Callewaert,Hans Ulrichts,Christian Duby,Dominique Tersago +13 more
TL;DR: Caplacizumab induced a faster resolution of the acute TTP episode than did placebo, and the platelet-protective effect of caplacIZumab was maintained during the treatment period.
Journal ArticleDOI
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.
Marie Scully,Vickie McDonald,Jamie Cavenagh,Beverley J. Hunt,I Longair,Hannah Cohen,Samuel J. Machin +6 more
TL;DR: Rituximab appears a safe and effective therapy that should be considered in conjunction with standard therapy on acute presentation of TTP and inpatient stay and relapse are significantly reduced in the ritUXimab cohort.